Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
NORWOOD, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in the following upcoming investor conferences.
B. Riley Securities Precision Oncology & Radiopharma Investor Conference
Format: Panel and one-on-one investor meetings
Panel Title: Unlocking the Full Potential of Nectin-4 Targeting Therapies
Date: February 28, 2025
Time: 8:00 a.m. ET
TD Cowen 45th Annual Health Care Conference
Format: Presentation and one-on-one investor meetings
Date: March 4, 2025
Time: 1:50 p.m. ET
Webcast:
Wedbush Securities Cardiometabolic Conference
Format: Panel
Panel Title: The Future of Fat: Exploring Alternative Targets in Obesity Beyond GLP1s
Date: March 10, 2025
Time: 10:05 a.m. ET
Leerink Partners Global Healthcare Conference 2025
Format: Presentation and one-on-one investor meetings
Date: March 12, 2025
Time: 1:40 p.m. ET
Webcast:
BMO 2025 Obesity Summit
Format: Panel and one-on-one investor meetings
Panel Title: Emerging Technologies
Date: March 25, 2025
Time: 1:15 p.m. ET
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit . Connect with us on , and .
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's restructuring, trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential,” "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.
INVESTOR CONTACT:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
Bruce Mackle
Managing Director
LifeSci Advisors, LLC
